COMPARE · Data as of August 21, 2026
GRFS vs HIMS
Verdict: Side-by-side breakdown using the Bull Rankings model. GRFS scored 70.8, HIMS scored 39.3 — GRFS leads.
Compare another set
GRFS
Grifols, S.A.
70.8
$8.00 · $5.4B
Score gap
31.5
GRFS leads
HIMS
Hims & Hers Health, Inc.
39.3
$31.13 · $7.3B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthHIMS+28.0%
- Strongest balance sheetGRFS1.17
- Highest qualityGRFS56 / 100
- Largest discount to fair valueGRFS-49%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
GRFS
stronger →← stronger
HIMS
56
Qualityreturns · margins · balance sheet
23
77
Growthrevenue & earnings expansion
93
96
Valuevaluation vs sector peers
29
GRFS is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
GRFS
HIMS
$570mC+
FCF
$62mC-
+9.4%B
Rev
+28.0%A-
1.17C
D/E
4.77D
10.4xA
P/E
—
0.19A
PEG
2.15C
—
P/S
2.8xB+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
GRFS
HIMS
49% below
Price vs fair valuelower is cheaper
777% above
~-4%/yr
Growth the price implies10-yr FCF · lower = less priced in
>60%/yr
+57%
1-yr DCF upside
-91%
+97%
5-yr DCF upside
-89%
+171%
10-yr DCF upside
-84%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
GRFS
Why this score
- Raising its dividend
- Foreign reporter (EUR)
HIMS
Why this score
- Diluting shareholders
The companies
GRFSGrifols, S.A.
Why now
Drug Manufacturers - General · market cap $5.4b. Down 22% from 52-week high of $10.23 — deep drawdown territory. PEG 0.19 — paying under fair value for the growth rate.
Moat
FCF converts 108% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Net margin 3.0% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
HIMSHims & Hers Health, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $7.3b. Down 52% from 52-week high of $65.30 — deep drawdown territory. Revenue growing +28% — in hypergrowth territory. 13 sell-side analysts rate this a Hold with a mean 1-yr target of $30.85 (implying -1% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 4.77 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Currently unprofitable (margin -5.5%) — path to GAAP profitability is the core thesis risk. Down 52% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where GRFS and HIMS diverge
On the headline score the gap is 31.5 points in favor of GRFS. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueGRFS 96.2 · HIMS 28.8GRFS +67.4
- QualityGRFS 55.9 · HIMS 22.7GRFS +33.2
- GrowthGRFS 77.0 · HIMS 92.8HIMS +15.8
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.